INTRODUCTION
Hepatitis C results from infection with HCV through exposure to infected blood. Approximately 170 million people worldwide, 3% of the world's population, are infected with HCV. Globally, it is estimated that 3-4 million people are newly infected each year, 1 with 50-80% of HCVinfected patients developing chronic hepatitis. 2 The most important sequelae of chronic HCV infection are progressive liver fibrosis leading to cirrhosis and hepatocellular carcinoma.
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Standard hepatitis C treatment consists of 24-48 weeks of combination therapy with pegylated interferon-α and ribavirin, which is dependent on HCV genotype, baseline HCV RNA titre and virological response. [4] [5] [6] Antiviral treatment should be considered in all chronically HCV-infected individuals; however, suboptimal response rates, abundant side effects and high treatment costs are major disadvantages of the current standard of care.
Development of new specifically targeted antiviral therapy against hepatitis C is eagerly anticipated. The target cells of HCV are hepatocytes and the natural hosts are humans and chimpanzees. Because of the lack of a cell culture system that supports efficient production of infectious particles, studying HCV entry has been difficult; for this reason, several surrogate in vitro systems have been developed to study the process of HCV entry into host cells.
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Recombinant HCV envelope glycoproteins have been successfully used as surrogate models to study virus-host interaction. Development of these functional models (HCV-like particles, recombinant HCV envelope glycoproteins, HCV pseudotype particles and vesicular stomatitis virus [VSV]/HCV pseudotypes) to analyse HCV entry has led to the identification of several cell surface molecules (including CD81, scavenger receptor B type 1, claudin-1, occludin, heparin sulphate, glucosaminoglycans, DC-SIGN, L-SIGN and low-density lipoprotein receptor) that are involved in HCV entry. [10] [11] [12] [13] [14] [15] [16] Recent data suggest that HCV entry requires a complex, tightly regulated interaction between the host and HCV.
VSV can be efficiently propagated in animal cells and readily forms pseudotypes with the envelope proteins of different viruses, including HCV. VSV pseudotype viruses expressing HCV E1/E2 chimeric proteins, containing transmembrane and cytoplasmic domains of the VSV-G glycoprotein, have been developed as HCV pseudotype models to study HCV binding and entry.
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JTK-652, a novel pyrrolopyridazin-derived HCV infection inhibitor, was identified by highthroughput screening of a large number of potential compounds (Central Pharmaceutical
Research Institute, Japan Tobacco Inc., Osaka, Japan). Using the in vitro HCV infection model consisting of HCV pseudotype VSV bearing HCV E1/E2 envelope proteins, JTK-652 was evaluated in multiple cell lines.
This study describes the preclinical development of this first-in-class infection inhibitor, followed by clinical studies testing safety, tolerability, pharmacokinetics and efficacy of JTK-652
in healthy volunteers and chronic hepatitis C patients.
The secreted alkaline phosphatase gene was inserted into the VSV genome, and its secretion from the infected cells into the culture supernatant was used to measure the viral infectivity. approved the study and all participants provided written informed consent before participating in any study-related activity. All studies were conducted in full compliance with the guidelines of Good Clinical Practice and the Declaration of Helsinki and were in accordance with the principles of Good Laboratory Practice. Safety pharmacology studies indicated that JTK-652 had no effect on the central nervous, cardiovascular, gastrointestinal, renal/urinary or respiratory systems in rats and dogs. In the
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JTK-652: a novel HCV infection inhibitor -CHAPTER 2 phototoxicity studies, a positive reaction was observed dose-dependently at ε300 mg/kg with single oral administration in mice (dose levels were 30, 100, 300 or 1,000 mg/kg). 
Safety, tolerability, pharmacokinetics and antiviral activity of JTK-652 in chronic hepatitis C patients
A total of 10 patients were enrolled and randomized into the study and 8 patients completed the study (7 active and 1 placebo). Demographic characteristics and baseline HCV RNA levels were similar in all dosed patients (Table 1) . Of the 10 patients in the study, all were male and Caucasian. Premature discontinuation occurred in two patients (one active and one placebo) on day 13 and day 19, respectively, because of a rash of mild intensity. Most patients, 8 out of 10 (80%), had been treated previously for HCV infection. All 10 dosed patients were fully compliant with study drug dosing.
With regard to safety and tolerability, administration of multiple oral doses of 100 mg JTK-652 or placebo three times daily for 28 days was safe and well-tolerated by 8 out of 10 male participants with chronic hepatitis C. There were no serious adverse events reported during this study. All adverse events (AEs) were of mild intensity. Treatment was not tolerated by two participants and they were withdrawn during the course of the study because of an AE. During treatment with 100 mg JTK-652 three times daily, one participant developed a rash on day 17.
The other participant developed a rash on day 12 during treatment with placebo three times daily. Both rashes were mild in intensity for these two participants and dosing was discontinued on day 19 and day 13, respectively. The rash disappeared within days after stopping JTK-652 administration and additional treatment was not necessary.
In total, 16 of the 46 AEs were considered as possibly related to the study medication. These related AEs were mainly skin and to a lesser extent gastrointestinal disorders. Except for the rash, there were no other clinically significant findings with regard to clinical laboratory, vital sign, body weight, ECG or physical examinations.
The pharmacokinetics of JTK-652 were studied and its appearance in plasma shortly after oral An investigation into the efficacy of JTK-652 found that after multiple dosing with 100 mg three times daily, no decrease in viral load was observed at the expected therapeutic dose level ( Figure 5 ). Individual maximum viral load change from baseline in all participants was within 0.5 log 10 IU/mL. Alanine aminotransferase levels were unaffected by treatment with multiple doses of 100 mg JTK-652 three times daily. 
DISCUSSION
This study is the first to describe the in vitro development of an HCV infection inhibitor and its clinical evaluation in chronic hepatitis C patients. Firstly, we described the in vitro antiviral properties of JTK-652 against HCV pseudotype virus, using multiple cell lines as target cells.
Secondly, we evaluated JTK-652 in chronic hepatitis C patients to assess safety, tolerability, pharmacokinetics and antiviral activity.
Although we are still far from understanding the details of HCV entry, recent data show that viral entry into target cells is a complex multistep process requiring the presence of several entry factors. 21 Initial attachment of the virion involves the tetraspanin CD81, glucosaminoglycans, heparan sulphate and the low-density lipoprotein receptor, followed by the sequential interaction with the scavenger receptor class B type I and the tight junction proteins claudin-1 and occludin. Furthermore, unidentified factors might be involved in the HCV entry process.
Previous studies described the crucial role of CD81 in the process of HCV infectivity. 14, 22, 23 Binding of CD81 to E2 is crucial for an HCV viral particle to penetrate into the host cell; however, recent studies showed that cell lines with little or no CD81 were capable of direct cell-to-cell viral transmission, suggesting a CD81-independent HCV entry process. [24] [25] [26] This indicates that there are at least two modes by which a virus can transmit from an infected cell to an uninfected cell:
cell-free transmission and cell-to-cell transmission. protein-expressing 293T cells. A possible explanation for the lack of inhibitory effect in these cells could be because of the amount of E1 and E2 expressed on the cell surface or because of differences of glycosylation as described before.
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The timing of adding JTK-652 on the viral inhibitory effect on HepG2 cells infected with pseudotype 1b virus was investigated. Maximum inhibition of viral infection was achieved when JTK-652 was added during inoculation with HCV pseudotype virus. The inhibitory effect was reduced upon delayed addition of JTK-652 to the assay system and little inhibitory effect was observed when JTK-652 was added ≥3 h after the inoculation. In addition, because JTK-652
showed no inhibition of the replication of HCV replicon RNA, JTK-652 had apparently no effect on the replication process of HCV. 53
JTK-652: a novel HCV infection inhibitor -CHAPTER 2
Safety and tolerability experiments in animals showed a positive, dose-dependent skin reaction in the phototoxicity studies. Phototoxicity was observed in mice after drug exposure at a dose level of 1,000 mg/kg; therefore, when JTK-652 was administered to humans in clinical studies, safety measures were taken, such as avoiding sunlight exposure. Despite such measures being taken, 4 out of 12 healthy volunteers were withdrawn during the course of the study because of a rash of mild intensity. These events of rash were considered to be related to the study drug and as a consequence the study dose in the Phase Ib study in chronic hepatitis C patients was lowered. Because JTK-652 plasma pharmacokinetic parameters in healthy volunteers had revealed that 100 mg dosing appeared to be sufficient as far as C max , t max , AUC 0-∞ and t 1/2 were concerned, it was decided to reduce the dose for the first cohort of chronic hepatitis C patients from 400 to 100 mg three times daily.
Data of the Phase Ib study revealed that JTK-652 at 100 mg three times daily was well-tolerated in the patients; however, two patients (one placebo and one active) had to stop treatment prematurely because of a mild rash. As one of these patients had received placebo, the rash In summary, JTK-652 monotherapy did not decrease HCV RNA in chronic hepatitis C patients.
The majority of adverse events were mild and there were two premature discontinuations in the Phase Ib study because of rash. Further development of JTK-652 was discontinued.
Nevertheless, HCV infection inhibition remains a potential target for antiviral therapy within the HCV life cycle.
